TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Core Insights - TransCode Therapeutics, Inc. has appointed Jack E. Stover to its Board of Directors, enhancing its leadership team as it advances its immuno-oncology and RNA treatment pipeline for high-risk and advanced cancer [1][2]. Company Developments - Jack E. Stover brings over 30 years of executive leadership experience in life sciences, including drug development and diagnostics, which will be beneficial for TransCode's growth [1][2]. - Stover's previous roles include Chairman of Traws Pharma Inc., CEO of NorthView Acquisition Corp, and President of Interpace Biosciences, where he led significant mergers and acquisitions [2]. - The company is entering an exciting stage of development, with Stover expressing his commitment to advancing its mission to deliver a cancer-free future for patients [3].